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Abstract 
Background: Aneurysmal subarachnoid hemorrhage (SAH) is a serious condition associated with high mortality 
rates and long-term disability. We investigated the impact of fluid balance on neurologic outcome after adjustment 
for possible confounders related to intensive care therapy and extra-cerebral organ failure during the early phase after 
SAH.
Methods: In this retrospective study, we analyzed data from all 142 adult patients admitted to our university hospital 
surgical intensive care unit (ICU) with SAH between March 2004 and November 2010.
Results: The mean patient age was 54 ± 14 years, 62.7 % were female, and the median Hunt and Hess score was 3. 
The proportions of patients with poor outcome (Glasgow Outcome Score ≤3) were 58.4, 54.2, and 52.1 % at 3, 6, and 
12 months, respectively, after the SAH. The ICU and hospital mortality rates were both 12.7 %, and the median lengths 
of stay in the ICU and the hospital were 16 (IQ 7–25) and 26 (IQ 18–34) days, respectively. In multivariable analysis, 
older age and greater cumulative fluid balance within the first 7 days in the ICU were independently associated with a 
greater risk of poor outcome.
Conclusion: In this cohort of patients, older age and greater cumulative fluid balance were independently associ-
ated with a greater risk of poor outcome up to 1 year after the initial insult. Our data suggest that mild hypovolemia 
may be beneficial in the management of these patients.
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Background
Aneurysmal subarachnoid hemorrhage (SAH) is a seri-
ous condition, not only because of the relatively high 
associated mortality rates, but also because it is common 
in young adult patients, leading to long-term disability 
and loss of productivity [1]. The course of the disease can 
be prolonged, with considerable secondary brain injury 
as a result of delayed cerebral ischemia [2].
The ultimate goal of therapy in patients with acute SAH 
is to control bleeding, provide supportive care in the 
acute phase, maintain adequate cerebral perfusion, and 
prevent secondary cerebral insults, especially vasospasm 
and cerebral infarction [1, 3]. The “triple-H” therapy, 
including hypervolemia, hypertension, and hemodilu-
tion, has been proposed as an effective approach in the 
management of patients with SAH. However, several 
randomized controlled studies have demonstrated that 
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triple-H therapy does not improve cerebral blood flow, 
nor does it have a positive impact on the neurologic out-
come of patients with SAH [4, 5]; indeed, this approach 
may be harmful and increase therapeutic costs [5–7]. 
Hypervolemic therapy may, in particular, be associated 
with high rates of complications, including pulmonary 
edema, dilutional hyponatremia, coagulopathy, and aneu-
rysm rebleeding [8]. The possible confounding effects of 
other intensive care therapies, especially vasopressor and 
fluid regimens, as well as the impact of extra-cerebral 
organ failure during the early phase after SAH, have not 
been systematically considered in the previous literature.
The aim of our study was, therefore, to investigate the 
impact of fluid balance on neurologic outcome after 
adjustment for possible confounders related to intensive 
care therapy and extra-cerebral organ failure during the 
early phase after SAH. We hypothesized that mild hypo-
volemia would be associated with good neurologic out-
come in these patients.
Methods
We included all adult (>18 years old) patients admitted to 
our 50-bed surgical intensive care unit (ICU) with SAH 
from March 2004 until November 2010. Patients were 
identified retrospectively using codes from the Interna-
tional Classification of Diseases-10 (ICD-10).
Ethics, consent, and permissions
The study was approved by the institutional review board 
of Friedrich Schiller University Hospital, Jena, Germany 
(Bachstrasse 18, 07743 Jena). Informed consent was waived 
due to the retrospective, anonymous nature of the analysis.
Data collection
Two investigators (LM and PD) reviewed the medi-
cal charts and computed tomography (CT) images of 
patients with SAH during the study period. The Hunt 
and Hess score [9] (Additional file 1: Table S1), recorded 
prospectively by the referring physician at the onset of 
symptoms, was noted. The World Federation of Neuro-
logical Surgeons clinical grading scale (WFNS) [10] was 
calculated retrospectively using the initial Glasgow Coma 
Scale (GCS) score [11]. The extent of the SAH was graded 
according to the Fisher scale [12] (Additional file 1: Table 
S1), which assesses the amount of bleeding seen on the 
initial head CT scan. Complications related to SAH were 
also recorded and included the occurrence of vasospasm, 
hydrocephalus, and cerebral infarction (confirmed by CT 
imaging).
Physiologic, hemodynamic, and therapeutic data from 
the ICU stay were collected and automatically recorded 
by a patient data management system (Copra Sys-
tem GmbH, Sasbachwalden, Germany). Data recorded 
prospectively on admission included age, sex, primary 
and secondary admission diagnoses, and surgical pro-
cedures. The Simplified Acute Physiology Score (SAPS) 
II [13] was calculated on admission, and the Sequential 
Organ Failure Assessment (SOFA) score [14] was calcu-
lated daily by the physician in charge of the patient using 
a special sheet. In sedated patients, the GCS measured 
prior to initiation of sedation was considered.
Management of patients with SAH
An initial cerebral CT scan was performed routinely 
in all patients on arrival to the emergency room, after 
hemodynamic stabilization. In patients with CT evidence 
of increased intracranial pressure (ICP), massive hemor-
rhage (Hunt and Hess grade 4), brain edema, and no pos-
sibility for appropriate neurologic assessment because of 
ongoing analgosedation or severe impairment of the con-
scious level (GCS < 8), extraventricular drains were surgi-
cally inserted. In some patients with massive brain edema 
or hemorrhage, craniectomy was performed. Cerebral 
angiography was performed in all patients within 12 h of 
admission to the hospital.
On admission to the ICU, blood samples were rou-
tinely drawn to obtain a complete blood picture, serum 
creatinine, blood urea, C-reactive protein, bilirubin lev-
els, activated prothrombin time (aPTT), and serum elec-
trolytes (sodium and potassium). These parameters were 
measured at least once daily thereafter (at 6:00 a.m.) dur-
ing the ICU stay. Fluid intake (enteral and parenteral) 
and output (urinary output, drains, and gastrointestinal 
losses) were measured and recorded hourly in the elec-
tronic charts. Insensible water loss was estimated hourly 
by the nurse in charge of the patient according to body 
mass index, body temperature, and the presence of 
mechanical ventilation [15].
According to our standard operative procedures 
(SOPs), patients with SAH were kept with a head-ele-
vated position of 30°–45° with the head aligned to the 
body axis to avoid venous congestion. Pressure transduc-
ers were placed at the level of the ears. Central venous 
pressure (CVP) was measured and recorded every 4 h in 
the neutral position. In mechanically ventilated patients, 
the minute volume was adjusted to keep PCO2 within the 
normocapnic range (4.7–6.0  kPa). Patients with exter-
nal ventricular drains had continuous monitoring of 
ICP and cerebral perfusion pressure (CPP), which was 
displayed as the difference between mean arterial and 
ICP. Vasospasm was assessed using transcranial Doppler 
(TCD) on a daily basis and, if present, graded into mild 
(≥120 <160 cm/s), moderate (≥160 <200 cm/s), or severe 
(≥200 cm/s) according to the maximal flow in any vessel. 
A cerebral CT scan was performed routinely after each 
intervention if there was clinical suspicion of intracranial 
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complications, or every 3  days during the first 2  weeks 
after hospital admission to guide therapy.
The mean arterial blood pressure target was 
70–80 mmHg for the first 3 days after SAH or to main-
tain a CPP  >  65  mmHg in patients with external ven-
tricular drains. The target was set at a higher level after 
the third day to reach 80–90 mmHg in patients without 
evidence of vasospasm and between 90 and 100 mmHg 
in those with vasospasm for up to 2  weeks or until the 
vasospasm had resolved. These targets were achieved by 
the infusion of incremental doses of norepinephrine. In 
patients requiring high doses of norepinephrine (>0.4 µg/
kg/min), additional boli of crystalloids were considered at 
the discretion of the attending physician.
The target for fluid administration was to keep the daily 
fluid balance at zero or slightly negative (500–1000  ml/
day). This was achieved using infusion of balanced full-
electrolyte infusions (E153™; Serumwerk Bernburg 
AG, Bernburg, Germany, or Jonosteril™; Fresenius Kabi 
GmbH, Bad Homburg, Germany) at a basic rate of 1000–
1500 ml/day. Colloid solutions were additionally used in 
some patients when clinically indicated in the form of 6 % 
hydroxyethyl starch (130/0.4, Voluven™; Fresenius Kabi, 
Bad Homburg, Germany). Since June 30, 2005, 4 % gelatin 
solutions (Gelafusal™; Serumwerk Bernburg AG, Bern-
burg, Germany) have replaced hydroxyethyl starch as the 
colloid of choice in our institution. Synthetic colloids have 
been completely banned in our ICU since 2008.
Outcome assessment
Sepsis was defined as the presence of infection, docu-
mented or supposed, plus systemic manifestations of this 
infection, and severe sepsis was defined as sepsis with 
associated organ failure [16]. All patients who survived 
the initial hospital stay were routinely given follow-up 
appointments at the neurosurgery polyclinic at 3, 6, and 
12 months after SAH at which the neurologic status was 
examined and documented. Nine patients were lost to 
follow-up, but we were able to contact their next-of-kin 
by telephone to obtain the necessary information about 
neurologic outcome. The Glasgow Outcome Score (GOS) 
[17] was calculated retrospectively according to the avail-
able data: grade 1, death; grade 2, persistent vegetative 
state; grade 3, severe disability; grade 4, moderate disabil-
ity, somewhat disabled but still independent for daily life; 
and grade 5, good recovery, although minor neurologic 
or psychological deficits could be present. Patients were 
stratified as having a poor (GOS ≤ 3) or good (GOS 4–5) 
outcome at 3, 6, and 12 months.
Statistical analysis
Data were analyzed using SPSS 16.0 for windows 
(SPSS Inc, Chicago, IL, USA). Nonparametric tests of 
comparison were used for variables evaluated as not being 
normally distributed. Difference testing between groups 
was performed using Student’s t test, Mann–Whitney U 
test, Chi-square test, or Fisher’s exact test as appropriate. 
Analysis of variance (ANOVA) was used to assess differ-
ences between groups over time with a post hoc Mann–
Whitney U test to assess the differences at each time point.
To define the possible factors associated with poor out-
come in SAH, we performed multivariable logistic regres-
sion analyses, with poor outcome (GOS ≤ 3) at 3, 6, and 
12 months after the SAH, as the dependent variable. The 
variables considered for this analysis were age, sex, SAPS 
II on admission to the ICU, the maximum degree of 
extracranial organ dysfunction/failure as assessed by the 
maximum SOFA subscores during the ICU stay, duration 
of mechanical ventilation, the initial WFNS and Hunt 
and Hess score, the Fisher score from the first CT scan 
following the onset of SAH, localization of the ruptured 
aneurysm, the type of primary intervention, the mean 
hemoglobin level and the lowest mean arterial blood 
pressure during the first week in the ICU, the occur-
rence of infection or severe sepsis during the ICU stay, 
the cumulative fluid balance and the maximum dose of 
norepinephrine within the first week in the ICU, the use 
of colloids during the ICU stay, the occurrence of compli-
cations (vasospasm, hydrocephalus, and cerebral infarc-
tion) during the ICU stay, and the maximum sodium 
concentration during the ICU stay. To reduce the num-
ber of covariates in the multivariable models, we adopted 
a forward, stepwise approach with entry and removal 
based on a univariate p value of 0.2. Collinearity between 
variables was excluded before modeling (R2  >  0.6), and 
none of the covariates was colinear. A Hosmer and Leme-
show goodness-of-fit test was performed, and odds ratios 
(OR) with 95 % confidence intervals (CI) were computed.
All statistics were two tailed. A p value <0.05 was 
considered to be significant. Continuous variables are 
presented as mean ± standard deviation or median [25–
75 % interquartile range (IQ)] and categorical variables as 
number and percentage, unless otherwise indicated.
Results
Characteristics of the study cohort
During the study period, 142 patients were admitted to 
our ICU after aneurysmal SAH [mean age 54 (SD 14) 
years, 62.7  % female]. The characteristics of the study 
group on admission to the ICU are given in Table 1. The 
median Hunt and Hess score was 3 (IQ 2–4), and the 
median WFNS was 3 (2–4). Aneurysms of the anterior 
circulation were responsible for 87.4 % of the cases (Addi-
tional file 1: Table S2). Surgical clipping was performed in 
102 patients (71.8 %) and external ventricular drainage in 
131 patients (92.3 %) (Additional file 1: Table S2).
Page 4 of 12Sakr et al. Ann. Intensive Care  (2016) 6:25 
Morbidity and mortality
Vasospasm was the most commonly reported complica-
tion and occurred in 65.5 % of patients (n = 93). Moder-
ate and severe vasospasm were present in 43.8 and 32.6 % 
of patients, respectively, after a median of 5 days (IQ 3–7) 
and lasted for a median of 9 days (IQ 6–17). Hydrocepha-
lus occurred in 83 (58.5 %) and cerebral infarction in 81 
(57.0  %) patients (Table  2). The ICU and hospital mor-
tality rates were both 12.7 %, and the median lengths of 
stay in the ICU and the hospital were 16 (IQ 7–25) and 
26 (IQ 18–34) days, respectively. At 3, 6, and 12 months 
after onset of the aneurysmal SAH, 58.4, 54.2, and 52.1 % 
of patients, respectively, had a poor outcome (GOS ≤ 3).
The impact of SAH‑related factors on outcome
Patients who had a poor outcome (GOS  ≤  3) at 3, 
6, and 12  months were older, had higher Hunt and 
Hess, WFNS and Fisher scores, and more commonly 
required external ventricular drainage, craniectomy, 
and ventriculoperitoneal shunts compared with those 
who had good outcomes (GOS 4–5) (Additional file  1: 
Table S3). The frequencies of hydrocephalus and cer-
ebral infarction were higher in patients with poor than in 
those with good outcome at 3, 6, and 12 months (Addi-
tional file 1: Table S4). Although the occurrence of vasos-
pasm was similar, the severity of vasospasm was worse in 
patients with poor outcome compared with those with 
good outcome throughout the follow-up period (Addi-
tional file 1: Table S4).
The impact of severity of illness, organ function, and ICU 
interventions on outcome
SAPS II and SOFA scores and the maximum sodium 
concentration within 24 h of admission to the ICU were 
higher in patients with poor than in those with good out-
comes after 3, 6, and 12  months (Table  3). Hemoglobin 
Table 1 Characteristics of  the study cohort on  admission 
to the ICU
GCS Glasgow Coma Scale, IQ interquartile range, SAPS II Simplified Acute 
Physiology Score II, SD standard deviation, SOFA sequential organ failure 
assessment, WFNS World Federation of Neurological Surgeons
n = 142
Age, years, mean ± SD 54 ± 14
Sex, female, n (%) 89 (62.7)
Source of admission, n (%)
 Emergency room 49 (34.5)
 Transferred from another hospital 93 (65.5)
Hunt and Hess score, n (%)
 1 10 (7.0)
 2 36 (25.4)
 3 39 (27.5)
 4 25 (17.6)
 5 32 (22.5)
WFNS-classification, n (%)
 1 35 (24.6)
 2 33 (23.2)
 3 13 (9.2)
 4 29 (20.4)
 5 32 (22.5)
GCS, median (IQ) 13 (7–14)
Fisher’s score, n (%)
 1 1 (0.7)
 2 17 (12.0)
 3 32 (22.5)
 4 92 (64.8)
Severity scores, mean ± SD
SAPS II 37.9 ± 14.5
SOFA score 5.9 ± 2.7
Table 2 Morbidity and mortality
ICU intensive care unit, IQ interquartile range, TCD transcranial Doppler
* 41 patients with one infarcted area, 34 patients with two infarcted areas, and 6 
patients with 3 infarcted areas
† 50 patients with one area of vasospasm and 43 patients with two areas 
of vasospasm; 76 cases were detected with TCD; 13 detected with TCD and 
angiography; and 4 detected only through angiograph
Cerebral infarction
 n (%) 81* (57.0)
 Territory, n (%)
  Anterior cerebral artery 50 (61.7)
  Middle cerebral artery 67 (82.7)
  Posterior cerebral artery 10 (12.3)
 Vasospasm-related infarction 54 (42.5)
Hydrocephalus, n (%) 83 (58.5)
Vasospasm
 n (%) 93† (65.5)
 Localization, n (%)
  Anterior cerebral artery 47 (50.5)
  Middle cerebral artery 87 (93.5)
  Posterior cerebral artery 1 (1.1)
  Basilar artery 1 (1.1)
 Severity of vasospasm‡, n (%)
  Mild (≥ 120 < 160 cm/s) 21 (23.6)
  Moderate (≥ 160 < 200 cm/s) 39 (43.8)
  Severe (≥ 200 cm/s) 29 (32.6)
Mortality rate, n (%)
 ICU mortality 18 (12.7)
 Hospital mortality 18 (12.7)
 ICU stay (days) median (IQ) 16 (7–25)
 Hospital stay (days) median (IQ) 26 (18–34)
Glasgow Outcome Score ≤3
 After 3 months 83 (58.4)
 After 6 months 77 (54.2)
 After 12 months 74 (52.1)
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levels were similar irrespective of outcome over the first 
4 days in the ICU and were higher thereafter in patients 
who had a good outcome compared with those with poor 
outcomes (Fig. 1). Patients who had a poor outcome after 
3, 6, and 12 months were more likely to need mechanical 
ventilation and vasopressor support to maintain the tar-
get blood pressure during the ICU stay than patients with 
good outcomes (Additional file 1: Table S5), but the doses 
of vasopressors (norepinephrine) were similar in the two 
groups. Infections, predominantly those of respiratory 
origin, and severe sepsis occurred more commonly, and 
the degree of organ dysfunction/failure was greater in 
patients who had poor compared with those with good 
outcomes throughout the follow-up period (Additional 
file 1: Table S5). Patients who had a poor outcome had a 
greater incidence of respiratory and cardiovascular fail-
ure during the ICU stay compared with patients who had 
good outcomes (Additional file 1: Table S5). 
Fluid balance within 24 h of admission to the ICU was 
similar in patients who had poor and those who had 
good outcomes at 3, 6, and 12 months; however, patients 
who had good outcomes achieved more negative fluid 
balances during the ICU stay up to the 7th day (Fig.  2; 
Table 4), despite markedly lower rates of diuretic therapy. 
This was mainly achieved by higher urinary outputs in 
patients who had good compared with those who had 
poor outcomes (Additional file  1: Figure S1). CVP val-
ues were similar within 24 h of admission to the ICU but 
were consistently lower in patients who had good com-
pared with those who had poor outcomes up to 7  days 
in the ICU (Table 4 and Additional file 1: Figure S2). The 
mean arterial blood pressure was similar during the first 
4 days in the ICU but was higher thereafter, up to 7 days 
in the ICU, in patients who had good compared with 
those who had poor outcomes (Fig. 3).
Multivariable adjustment
In multivariable analysis, older age and greater cumula-
tive fluid balance within the first 7 days in the ICU were 
independently associated with a higher risk of poor out-
come throughout the follow-up period (Table 5). Higher 
Fisher scores on hospital admission and the duration of 
mechanical ventilation during the ICU stay were inde-
pendently associated with a higher risk of poor outcome 
at 3 and 6 months. Higher WFNS on hospital admission, 
higher sodium levels in the ICU, and the occurrence of 
infection during the ICU stay were additionally found to 
be associated with an increased risk of poor outcome at 
1 year after the onset of SAH.
Discussion
The main findings of our study were that in patients 
with aneurysmal SAH: (1) patients who had good out-
comes achieved more negative fluid balances after the 
day of admission up to the 7th day during the ICU stay 
than those who had poor outcomes; (2) the mean arterial 
blood pressure was similar during the first 4 days in the 
ICU but was higher thereafter in patients with good com-
pared to those with poor outcomes for up to 7 days in the 
ICU; and (3) greater cumulative fluid balance within the 
Table 3 Severity of illness, use of vasopressors, need for mechanical ventilation, and physiologic parameters on admis-
sion to the ICU according to the GOS
aPTT activated partial thromboplastin time
† p < 0.01; ‡ p < 0.001
GOS after 3 months GOS after 6 months GOS after 12 months
GOS 1–3 GOS 4–5 GOS 1–3 GOS 4–5 GOS 1–3 GOS 4–5
SAPS II, mean ± SD 42.2 ± 13.2 31.6 ± 14.1‡ 42.5 ± 13.3 32.3 ± 14.0‡ 42.6 ± 13.2 32.6 ± 14.1‡
SOFA score, total, mean ± SD 6.7 ± 2.3 4.8 ± 2.7‡ 6.8 ± 2.3 4.9 ± 2.8‡ 6.7 ± 2.2 5.0 ± 2.9‡
SOFA score, without GCS, mean ± SD 4.6 ± 2.4 2.9 ± 2.2‡ 4.6 ± 2.4 3.0 ± 2.3‡ 4.6 ± 2.5 3.1 ± 2.3†
Physiologic parameters, median (IQ)
 Creatinine (µmol/l) 68 (61–81) 68 (70–79) 69 (61–83) 67 (60–77) 70 (61–84) 67 (61–77)
 Bilirubin (µmol/l) 9 (7–14) 10 (8–14) 9 (7–14) 10 (7–14) 9 (7–14) 10 (8–15)
 Platelets (1000/µl) 209 (183–266) 218 (197–248) 205 (180–265) 219 (198–251) 204 (178–267) 220 (198–248)
 aPTT (s) 30 (28–33) 29 (27–35) 30 (28–33) 30 (27–35) 30 (27–33) 30 (27–36)
 Leukocytes (Tsd/µl) 13.5 (10.5–17.0) 11.8 (9.4–14.8) 13.5 (10.7–17.1) 11.8 (9.2–15.2) 13.5 (10.7–17.0) 11.9 (9.2–15.3)
 C-reactive protein (mg/l) 7.8 (3.4–16.0) 6.3 (3.0–15.0) 8.1 (3.4–16.1) 6.3 (3.0–14.9) 7.5 (3.4–15.5) 6.6 (3.0–15.1)
 Hemoglobin (mmol/l) 7.8 (7.2–8.6) 8.2 (7.7–8.4) 7.8 (7.2–8.6) 8.2 (7.6–8.4) 7.8 (7.2–8.6) 8.2 (7.6–8.4)
 Hematocrit 0.36 (0.33–0.40) 0.37 (0.34–0.39) 0.36 (0.33–0.40) 0.37 (0.34–0.39) 0.36 (0.33–0.40) 0.37 (0.34–0.39)
 Sodium (min) (mmol/l) 139 (137–142) 138 (137–139) 139 (137–142) 138 (137–139) 139 (137–142) 138 (137–140)
 Sodium (max) (mmol/l) 145 (142–148) 142 (141–144)‡ 145 (143–148) 142 (141–144)‡ 145 (143–148) 142 (141–145)‡
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Fig. 1 Box blots representing the time course of hemoglobin levels in mmol/l over the first week in the ICU in patients with poor (Glasgow 
Outcome Score; GOS ≤ 3, dark boxes) versus good (GOS > 3, light boxes) outcome at 3, 6, and 12 months after the onset of SAH. ANOVA: 3 months: 
p = 0.085, 6 months: p = 0.125, 12 months: p = 0.114. *p < 0.05 compared with patients with good outcome
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Fig. 2 Box blots representing fluid balance in ml over the first week in the ICU in patients with poor (Glasgow Outcome Score; GOS ≤ 3, dark boxes) 
versus good (GOS > 3, light boxes) outcome at 3, 6, and 12 months after the onset of SAH. ANOVA: p < 0.001 at 3, 6, and 12 months. *p < 0.05 com-
pared with patients with good outcome
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Fig. 3 Box blots representing the mean arterial pressure in mmHg over the first week in the ICU in patients with poor (Glasgow Outcome Score; 
GOS ≤ 3, dark boxes) versus good (GOS > 3, light boxes) outcome at 3, 6, and 12 months after the onset of SAH. ANOVA: 3 months: p = 0.258, 
6 months: p = 0.163, 12 months: p = 0.125. *p < 0.05 compared with patients with good outcome
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first 7 days in the ICU was independently associated with 
a higher risk of poor outcome throughout the follow-up 
period.
Although the incidence of vasospasm was similar, the 
severity of vasospasm was higher in patients with poor 
outcomes compared with those with good outcomes 
throughout the follow-up period. This type of association 
has been reported consistently in previous studies [18–
23]. Vasospasm is a major determinant of brain ischemia 
after SAH [24] and may be responsible for delayed neu-
rologic deterioration and severe disability [22, 23]. As 
expected, the higher rates of vasospasm in our study in 
patients with poor outcome were associated with higher 
incidences of cerebral infarction and hydrocephalus 
as well as the need for insertion of external ventricular 
drains and decompression craniectomy compared with 
patients with good outcomes [25, 26]. The relatively high 
prevalence of vasospasm and cerebral infarctions in our 
study can be explained by the severity of illness of our 
patients, as evident from the high Hunt and Hess score 
and WFNS. Our institution is the largest tertiary care 
referral center in the state of Thuringia, Germany, in 
which in-house neurosurgical and interventional radi-
ologists are available 24 h/day. We therefore receive the 
most severe cases of SAH.
An interesting finding of our study was that greater 
cumulative fluid balance within the first 7  days in the 
ICU was independently associated with a higher risk of 
poor outcome, suggesting that mild hypovolemia may 
improve neurologic outcome in these patients. Indeed, 
fluid balance is not a surrogate for assessment of blood 
volume [2, 27] and CVP does not precisely reflect intra-
vascular volume status [2, 28]. However, an expert panel 
has acknowledged that close monitoring of fluid input 
and output should be the primary assessment tool in 
these patients, in addition to physical findings and clinical 
data [2]. Although these recommendations also implied 
that euvolemia should be targeted in patients with SAH 
[2], current evidence does not refute the possible ben-
eficial effects of mild hypovolemia on outcome in these 
patients. Maintaining normovolemia may necessitate the 
use of relatively large fluid volumes, which may lead to 
cerebral edema and negatively influence neurologic recov-
ery. Although hypovolemia has been described as being 
associated with higher rates of cerebral infarction [29, 
30], these observations were not systematically adjusted 
for possible confounding factors and did not take into 
account the degree and timing of hypovolemia. In a recent 
retrospective cohort, Martini et  al. [21] found that posi-
tive fluid balance was associated with increased rates of 
vasospasm and also with increased ICU lengths of stay 
after aneurysmal SAH. Similar results have been reported 
in a more recent propensity score-matched analysis [31]. 
Unfortunately, these studies did not analyze the possible 
impact of negative fluid balance on outcome [21, 31].
The hemodynamic pattern following SAH is quite 
complex. Sympathetic hyperactivity may evoke a hyper-
dynamic and hypovolemic state [32]. Conversely, in a 
large multicenter cohort of 204 patients, hemodynamic 
measurements early after SAH revealed a heart failure-
like afterload mismatch with rather elevated global end-
diastolic volume index (GEDVI), signifying increased 
preload [33]. Nonetheless, decreased GEDVI and car-
diac index, in addition to increased systemic vascular 
resistance, were independently associated with the risk 
of delayed cerebral ischemia [33]. Goal-directed therapy 
using transpulmonary thermodilution monitoring has 
been reported to be effective in reducing the frequency 
Table 5 Summary of multivariable analysisa with poor outcome (GOS ≤ 3) as the dependent variable
CI confidence interval, OR odds ratio
† Hosmer and Lemeshow Chi-square = 5.342 (p = 0.721); pseudo-R2 0.699
‡ Hosmer and Lemeshow Chi-square = 5.11 (p = 0.746); pseudo-R2 0.738
¶ Hosmer and Lemeshow Chi-square = 6.586 (p = 0.582); pseudo-R2 0.68
a Forward stepwise logistic regression analysis with poor outcome (GOS ≤ 3) as the dependent variable. Only variables that were retained at the final step are 
displayed
After 3 months† After 6 months‡ After 12 months¶
OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value
Age (per year) 1.13 (1.06–1.20) <0.001 1.13 (1.06–1.21) <0.001 1.08 (1.03–1.14) 0.003
Fluid balance within 7 days (per l) 1.24 (1.08–1.42) 0.002 1.21 (1.06–1.39) 0.006 1.19 (1.04–1.36) 0.011
Fisher’s score (per point) 7.41 (2.43–22.57) <0.001 5.33 (1.59–17.8) 0.007 2.40 (0.90–6.38) 0.079
Mechanical ventilation (per day) 1.10 (1.04–1.16) <0.001 1.10 (1.04–1.18) 0.002 – –
WFNS score (per point) – – 1.59 (0.97–2.61) 0.064 1.84 (1.15–2.93) 0.011
Maximum sodium levels in the ICU (per mmol/l) – – – – 1.2 (1.03–1.39) 0.021
Infection during the ICU stay – – – – 7.14 (2.18–23.39) 0.001
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of vasospasm and cardiopulmonary complications com-
pared with standard therapy, but it did not influence 
functional outcomes at 3  months [34]. The absence of 
a positive effect on outcome does not support routine 
aggressive volume administration and inotropic therapy 
to maintain euvolemia and high cardiac index. We may 
assume that mild permissive hypovolemia would be well 
tolerated and associated with good neurologic outcome 
early after SAH. This may be supported by vasopressor-
induced hypertension as used in our institution during 
the study period. This approach has been reported to be 
safe, even in patients with coexisting unruptured, unpro-
tected intracranial aneurysms [35]. Further randomized 
studies are needed to confirm this assumption.
In our study, hemoglobin levels were not found to have 
an impact on outcome after adjustment for possible con-
founders. Our data do not, therefore, support hemodilu-
tion as a therapeutic approach for aneurysmal SAH. As 
higher arterial blood pressure was the main target of our 
therapy and levels were maintained within the hypertensive 
range in all our patients, it is not possible to elaborate on 
the efficacy of using hypertensive therapy in these patients.
Our analysis has some limitations. First, a cause–
effect relationship cannot be established with certainty 
because of the retrospective nature of the analysis and 
the inherent limitations of the multivariable analysis. 
However, our data should be considered to be hypoth-
esis generating. Second, management of SAH may vary 
among institutions and geographic regions, which hin-
ders the generalizability of our results. We also reported 
on patients with a relatively severe form of SAH admit-
ted to a single center, and our findings may, therefore, not 
be applicable to patients with milder forms of the dis-
ease. However, the multivariable analyses account for the 
confounding effects of therapeutic interventions and the 
heterogeneity of case-mix. Moreover, the single-center 
nature of the study may be an advantage as it limits the 
impact of variations in practice that can be a confound-
ing factor in multicenter studies. Third, the multivariable 
analysis considers only variables included in the statisti-
cal model, and the influence of unmeasured variables 
cannot be accounted for. Third, numerous comparisons 
have been reported in our study potentially creating type 
II errors. However, this is not expected to have influ-
enced the results of the multivariable analysis, which is 
not subject to such errors. Finally, we were not able to 
assess symptomatic vasospasm due to the relatively large 
number of mechanically ventilated patients in our study. 
Nonetheless, current recommendations on the manage-
ment of patients with SAH suggest reporting only radio-
graphic evidence of cerebral infarction and functional 
outcome as the primary outcome measures in these 
patients as the term “symptomatic vasospasm” implies 
the use of some subjective criteria, which may be difficult 
to assess in clinical practice [2].
Conclusion
In this cohort of patients with aneurysmal SAH, older 
age and greater cumulative fluid balance within the first 
7  days in the ICU were independently associated with a 
greater risk of poor outcome for up to 1 year after the ini-
tial insult. Our data suggest that mild hypovolemia may be 
beneficial in the treatment of these patients. Randomized 
controlled trials are needed to confirm this observation.
Authors’ contributions
YS, PD, LM, and KE conceived the study. LM, CS, PD, and MZ participated in 
data collection. YS, CS, and LM performed the statistical analyses. YS, CS, and 
MZ drafted the manuscript. KR, RK, and CE revised the draft. All authors read 
and approved the final manuscript.
Author details
1 Department of Anesthesiology and Intensive Care, Uniklinikum Jena, 
Erlanger Allee 101, 07743 Jena, Germany. 2 Department of Neurosurgery, 
Uniklinikum Jena, Erlanger Allee 101, 07743 Jena, Germany. 3 Department 
of Intensive Care, Federal University of Espírito Santo, R. Natalina D. Carneiro 
874, Vitória 29060490, Brazil. 4 Department of Anaesthesiology and Intensive 
Care, Theodor Bilharz Institute, Cairo, Egypt. 5 Department of Anesthesiology 
and Intensive Care, Friedrich-Schiller-University, Erlanger Allee 101, 07743 Jena, 
Germany. 
Acknowledgements
We would like to thank Dr. Karen Picket for her editorial assistance.
The study was performed in the Departments of Anesthesiology and Intensive 
Care and Neurosurgery, Uniklinikum Jena.
Competing interests
The authors declare that they have no competing interests.
Funding
The study was supported by institutional funding from the Department of 
Anesthesiology and Intensive Care Unit and the Department of Neurosurgery, 
Uniklinikum Jena, Erlanger Allee 101, 07743 Jena, Germany.
Received: 20 December 2015   Accepted: 14 March 2016
References
 1. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 
2007;369:306–18.
 2. Diringer MN, Bleck TP, Claude HJ III, Menon D, Shutter L, Vespa P, et al. 
Critical care management of patients following aneurysmal subarachnoid 
hemorrhage: recommendations from the Neurocritical Care Society’s 
Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211–40.
 3. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, 
Higashida RT, et al. Guidelines for the management of aneurysmal 
subarachnoid hemorrhage: a guideline for healthcare professionals from 
the American Heart Association/American Stroke Association. Stroke. 
2012;43:1711–37.
Additional file
Additional file 1. Additional online supplement.
Page 12 of 12Sakr et al. Ann. Intensive Care  (2016) 6:25 
 4. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et al. Effect 
of hypervolemic therapy on cerebral blood flow after subarachnoid 
hemorrhage: a randomized controlled trial. Stroke. 2000;31:383–91.
 5. Egge A, Waterloo K, Sjoholm H, Solberg T, Ingebrigtsen T, Romner B. 
Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal 
subarachnoid hemorrhage: a clinical, prospective, randomized, controlled 
study. Neurosurgery. 2001;49:593–605.
 6. Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the 
prevention of delayed ischemic neurological deficits with hypertension, 
hypervolemia, and hemodilution therapy following subarachnoid hemor-
rhage. J Neurosurg. 2003;98:978–84.
 7. Treggiari MM, Deem S. Which H is the most important in triple-H therapy 
for cerebral vasospasm? Curr Opin Crit Care. 2009;15:83–6.
 8. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. 
Treatment of ischemic deficits from vasospasm with intravascular 
volume expansion and induced arterial hypertension. Neurosurgery. 
1982;11:337–43.
 9. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the 
repair of intracranial aneurysms. J Neurosurg. 1968;28:14–20.
 10. Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A 
universal subarachnoid hemorrhage scale: report of a committee of the 
World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychia-
try. 1988;51:1457.
 11. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: 
a practical scale. Lancet. 1974;2:81–4.
 12. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to suba-
rachnoid hemorrhage visualized by computerized tomographic scan-
ning. Neurosurgery. 1980;6:1–9.
 13. Le Gall J, Lemeshow S, Saulnier F. A new Simplified Acute Physiology 
Score (SAPS II) based on a European/North American multicenter study. 
JAMA. 1993;270:2957–63.
 14. Vincent JL, Moreno R, Takala J, Willatts S, De MA, Bruining H, et al. The 
SOFA (Sepsis-related Organ Failure Assessment) score to describe organ 
dysfunction/failure. On behalf of the Working Group on Sepsis-Related 
Problems of the European Society of Intensive Care Medicine. Intensive 
Care Med. 1996;22:707–10.
 15. Cox P. Insensible water loss and its assessment in adult patients: a review. 
Acta Anaesthesiol Scand. 1987;31:771–6.
 16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 
SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. 
Crit Care Med. 2003;31:1250–6.
 17. Jennett B, Bond M. Assessment of outcome after severe brain damage. 
Lancet. 1975;1:480–4.
 18. de Oliveira JG, Beck J, Ulrich C, Rathert J, Raabe A, Seifert V. Comparison 
between clipping and coiling on the incidence of cerebral vasospasm 
after aneurysmal subarachnoid hemorrhage: a systematic review and 
meta-analysis. Neurosurg Rev. 2007;30:22–30.
 19. Dorsch NW. Therapeutic approaches to vasospasm in subarachnoid 
hemorrhage. Curr Opin Crit Care. 2002;8:128–33.
 20. Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham JR, 
Manno EM, et al. Predictors of cerebral infarction in aneurysmal subarach-
noid hemorrhage. Stroke. 2004;35:1862–6.
 21. Martini RP, Deem S, Brown M, Souter MJ, Yanez ND, Daniel S, et al. The 
association between fluid balance and outcomes after subarachnoid 
hemorrhage. Neurocrit Care. 2012;17:191–8.
 22. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following 
aneurysmal subarachnoid hemorrhage. Stroke. 1985;16:562–72.
 23. Awad IA, Carter LP, Spetzler RF, Medina M, Williams FC Jr. Clinical 
vasospasm after subarachnoid hemorrhage: response to hypervolemic 
hemodilution and arterial hypertension. Stroke. 1987;18:365–72.
 24. Fisher CM, Roberson GH, Ojemann RG. Cerebral vasospasm with 
ruptured saccular aneurysm: the clinical manifestations. Neurosurgery. 
1977;1:245–8.
 25. Black PM. Hydrocephalus and vasospasm after subarachnoid hemor-
rhage from ruptured intracranial aneurysms. Neurosurgery. 1986;18:12–6.
 26. Woernle CM, Winkler KM, Burkhardt JK, Haile SR, Bellut D, Neidert MC, 
et al. Hydrocephalus in 389 patients with aneurysm-associated subarach-
noid hemorrhage. J Clin Neurosci. 2013;20:824–6.
 27. Hoff RG, van Dijk GW, Algra A, Kalkman CJ, Rinkel GJ. Fluid balance and 
blood volume measurement after aneurysmal subarachnoid hemor-
rhage. Neurocrit Care. 2008;8:391–7.
 28. Moretti R, Pizzi B. Inferior vena cava distensibility as a predictor of fluid 
responsiveness in patients with subarachnoid hemorrhage. Neurocrit 
Care. 2010;13:3–9.
 29. Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral 
infarction in patients with ruptured intracranial aneurysms: Is fluid restric-
tion harmful? Ann Neurol. 1985;17:137–40.
 30. Hasan D, Wijdicks EF, Vermeulen M. Hyponatremia is associated with cer-
ebral ischemia in patients with aneurysmal subarachnoid hemorrhage. 
Ann Neurol. 1990;27:106–8.
 31. Ibrahim GM, MacDonald RL. The effects of fluid balance and colloid 
administration on outcomes in patients with aneurysmal subarachnoid 
hemorrhage: a propensity score-matched analysis. Neurocrit Care. 
2013;19:140–9.
 32. Mutoh T, Kazumata K, Ajiki M, Ushikoshi S, Terasaka S. Goal-directed fluid 
management by bedside transpulmonary hemodynamic monitoring 
after subarachnoid hemorrhage. Stroke. 2007;38:3218–24.
 33. Yoneda H, Nakamura T, Shirao S, Tanaka N, Ishihara H, Suehiro E, et al. 
Multicenter prospective cohort study on volume management after 
subarachnoid hemorrhage: hemodynamic changes according to 
severity of subarachnoid hemorrhage and cerebral vasospasm. Stroke. 
2013;44:2155–61.
 34. Mutoh T, Kazumata K, Ishikawa T, Terasaka S. Performance of bed-
side transpulmonary thermodilution monitoring for goal-directed 
hemodynamic management after subarachnoid hemorrhage. Stroke. 
2009;40:2368–74.
 35. Reynolds MR, Buckley RT, Indrakanti SS, Turkmani AH, Oh G, Crobeddu E, 
et al. The safety of vasopressor-induced hypertension in subarachnoid 
hemorrhage patients with coexisting unruptured, unprotected intracra-
nial aneurysms. J Neurosurg. 2015;123:862–71.
